Skip to content

Analysis of the impact of an interdisciplinary cooperation between rheumatologists and dermatologists on the quality of care and earlier diagnosis of comorbidities for patients with psoriasis and psoriatic arthritis

Analysis of the impact of an interdisciplinary cooperation between rheumatologists and dermatologists on the quality of care and earlier diagnosis of comorbidities for patients with psoriasis and psoriatic arthritis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00020963
Enrollment
250
Registered
2020-04-09
Start date
2020-08-12
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

L40.0 M07

Interventions

Group 1: Primarily dermatologically patients with psoriasis vulgaris. The patients receive two visits (week 0 and week 24). If psoriasis arthritis shows up in visit 1 in week 0, rheumatological presen

Sponsors

Novartis Pharma GmbH
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Ability to give consent, age over 18, possession of a smartphone

Exclusion criteria

Exclusion criteria: Inability to give consent, age under 18, no Smartphone available

Design outcomes

Primary

MeasureTime frame
The primary goal of this study is to improve and measure the quality of care for psoriasis patients through closer networking of the treating doctors - here in particular rheumatologists and dermatologists. For this, in this project 1.) the actual state of the quality of care and the diagnosis of psoriasis and psoriatic arthritis patients will determined using data from the the first visit 1 in week 0. 2.) a stable communication and interaction structure between rheumatologists and dermatologists will be established bevor inclusion of the first patient. 3.) After building this structure, the quality of care of psoriasis and psoriasis arthritis patients and their satisfaction with their care will be evaluated after the 3rd visit in week 24.

Secondary

MeasureTime frame
1. Comparison of the data from the study with data from the Pso-Best study (German Psoriasis-Registry) 2. Evaluation of our Pso / PsA app

Countries

Germany

Contacts

Public ContactAstrid Schmieder

Klinik für Dermatologie, Universitätsmedizin Mannheim

astrid.schmieder@umm.de0621-383-2280

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 13, 2026